Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo: A Randomized, Placebo-controlled, Double-blind Controlled Trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- Healthy volunteers taking 600 mg aspirin to raise gut permeability; the abstract does not give the number. Also Caco-2 cell cultures and human colon tissue from bowel resections
- Dose used in the study
- Oral PEA or cannabidiol or placebo in the human arm; dose not stated in the abstract
- Duration
- Single-dose lactulose-mannitol permeability test
- What was measured
- Urinary lactulose and mannitol after aspirin (in vivo); dextran flux across inflamed Caco-2 monolayers; claudin, receptor and aquaporin expression in human colon mucosa
What the authors reported
The trial found:\n- Aspirin raised absorption of lactulose and mannitol, and PEA or cannabidiol reduced that rise (p < 0.001).\n- In cell culture, PEA reduced inflammation-induced dextran flux through a PPAR-alpha dependent route.\n- In human mucosa, PEA prevented the inflammation-induced fall in TRPV1 and rise in PPAR-alpha transcription.
Limits of this study
Abstract only; the number of volunteers, the PEA dose and the crossover details are not given there. The in vivo model is aspirin-induced permeability in healthy people, not inflammatory bowel disease. Mechanistic study; no symptom outcomes.
Source
PubMed 30806665 · doi:10.1093/ibd/izz017
Entry checked against the abstract, supplied by Devlin. Sample size and dose not in the abstract on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.